Cancer drugs and the heart: importance and management

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

The biology of VEGF and its receptors

2003 • 9,272 citations

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

2010 • 6,542 citations

Estimates of the cancer incidence and mortality in Europe in 2006

2007 • 4,128 citations

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

2007 • 3,010 citations

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

1979 • 2,308 citations

Estimates of cancer incidence and mortality in Europe in 2008

2010 • 2,247 citations

Congestive heart failure in patients treated with doxorubicin

2003 • 2,070 citations

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

2004 • 1,574 citations

USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2

2009 • 1,262 citations

Cardiovascular Complications of Cancer Therapy

2009 • 1,172 citations

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

2006 • 1,126 citations

Anthracycline-Induced Cardiomyopathy

2010 • 1,028 citations

American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

2007 • 943 citations

Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

2007 • 912 citations

Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

2004 • 865 citations

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

2001 • 825 citations

Mechanisms and Models in Heart Failure

2005 • 815 citations

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

2007 • 765 citations

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

2008 • 728 citations

Prediction of venous thromboembolism in cancer patients

2010 • 710 citations

Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment

2005 • 707 citations

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

2011 • 705 citations

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

2010 • 670 citations

Adverse effects of anticancer agents that target the VEGF pathway

2009 • 527 citations

Cardioprotective interventions for cancer patients receiving anthracyclines

2011 • 515 citations

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

2010 • 511 citations

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

2011 • 507 citations

Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries

1993 • 448 citations

Anthracycline Cardiotoxicity: From Bench to Bedside

2008 • 443 citations

Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials

2010 • 416 citations

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

2010 • 398 citations

High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis

2011 • 397 citations

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

2010 • 396 citations

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

2007 • 385 citations

Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury

1997 • 383 citations

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

2008 • 379 citations

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

2010 • 348 citations

Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patients

2002 • 332 citations

Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.

1991 • 329 citations

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

2008 • 314 citations

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

2008 • 308 citations

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

2002 • 305 citations

Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1β and Anti-erbB2

2002 • 285 citations

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

2010 • 255 citations

Congestive heart failure is a rare event in patients receiving imatinib therapy

2007 • 252 citations

Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease

2007 • 252 citations

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

2010 • 246 citations

A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.

1984 • 240 citations

Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis

2010 • 225 citations

Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study

2005 • 211 citations

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

2009 • 194 citations

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

2011 • 184 citations

Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib

2011 • 165 citations

Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging—A pilot study

2001 • 159 citations

Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era

2003 • 136 citations

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

2009 • 134 citations

Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction

2004 • 129 citations

Cardiotoxicity with 5‐fluorouracil and capecitabine: more than just vasospastic angina

2010 • 123 citations

Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction

2002 • 115 citations

Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

2009 • 106 citations

Prinzmetal's angina during 5-fluorouracil chemotherapy

1987 • 100 citations

Assessment of Anthracycline Cardiomyopathy by Endomyocardial Biopsy

1994 • 83 citations

A Historical Perspective of Anthracycline Cardiotoxicity

2011 • 53 citations

Usefulness of Cardiac Resynchronization Therapy in Patients With Adriamycin-Induced Cardiomyopathy

2010 • 52 citations

The role of endomyocardial biopsy in the diagnosis and treatment of heart disease.

1989 • 46 citations

Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer

2011 • 45 citations

Mitoxantrone: an active, new antitumor agent with an improved therapeutic index

1987 • 30 citations

Overexpression of Vascular Endothelial Growth Factor 165 (VEGF₁₆₅) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis

2010 • 21 citations